Aspen Neuroscience prices $15 IPO, raising $140.6 million

Aspen Neuroscience, a clinical‑stage biotech developing autologous cell therapies for Parkinson’s disease, announced that it priced its initial public offering at $15.00 per share. The company sold 9,375,000 shares, generating gross proceeds of approximately $140.6 million, and will begin trading on Nasdaq under the ticker ASPE on October 30, 2026. Underwriters hold a 30‑day option to purchase up to an additional 1,406,250 shares.

The new capital will be used to advance the company’s lead candidate, sasineprocel, through later‑stage clinical trials, including a planned Phase 3 study. Investors now have the opportunity to acquire shares at the IPO price as trading commences.

  • 1The IPO was priced at $15.00 per share.
  • 2Aspen offered 9,375,000 shares in the offering.
  • 3Gross proceeds are expected to be about $140,625,000.
  • 4Trading is scheduled to start on Nasdaq on October 30, 2026 under the ticker ASPE.
  • 5Underwriters have a 30‑day option to buy up to 1,406,250 additional shares.
  • 6The offering is expected to close on November 2, 2026, subject to customary closing conditions.

Sources